Palmitoylethanolamide Reverses Paclitaxel-Induced Allodynia in Mice
Laboratory studyOther animalsWith gabapentin
This study tested palmitoylethanolamide together with gabapentin. Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.
- Design
- Laboratory study
- Subjects
- Mice with paclitaxel-induced chemotherapy peripheral neuropathy (CIPN)
- Dose used in the study
- PEA and gabapentin tested alone (ED50 9.2 and 67.4 mg/kg) and combined; also intraplantar, intrathecal and intracerebroventricular PEA; repeated PEA 30 mg/kg for 7 days
- Duration
- 7-day repeated dosing for tolerance testing
- What was measured
- Paclitaxel-induced allodynia, isobolographic drug interaction, PPAR-alpha involvement, and tolerance with repeated dosing
What the authors reported
This laboratory study found:
- Gabapentin and PEA each reversed paclitaxel-induced allodynia (ED50 67.4 and 9.2 mg/kg) and acted synergistically in combination.
- A PPAR-alpha antagonist blocked PEA's effect.
- PEA given into the paw, spinally, or into the brain also reversed allodynia.
- 7 days of repeated dosing kept its effect without tolerance.
Limits of this study
A mouse model of chemotherapy-induced neuropathy; it cannot show effect in people undergoing chemotherapy. Funding and conflicts not stated in the abstract.
Source
PubMed 27608657 · doi:10.1124/jpet.116.236182
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.